Lorlatinib is a potent, brain-penetrant, third-generation ALK/ROS1 TKI. We performed an analysis of CNS and non-CNS progression in patients with pretreated ALK+ NSCLC. Our results indicate that lorlatinib is active in the treatment and prevention of CNS metastases in patients with ALK+ NSCLC, including those who had progressed on crizotinib or second-generation TKIs. READ ARTICLE
Targeted Oncology Volume DOI:10.1007/s11523-020-00702-4
Authors: Bauer, T.M., Shaw, A.T., Johnson, M.L. et al.
Anaplastic lymphoma kinase (ALK) gene rearrangement occurs in 2%–4% of all non–small cell lung cancer (NSCLC). Treatment with targeted tyrosine kinase inhibitors (TKIs) has shown impressive clinical responses in these patients. Crizotinib was the first agent approved for front-line therapy of ALK-rearranged NSCLC after it demonstrated superior clinical benefit compared with chemotherapy. Eventually, all patients progress on crizotinib therapy, with the central nervous system (CNS) being the most common site. Several next-generation ALK inhibitors were evaluated in crizotinib-treated patients and found to be effective. Currently, ceritinib, alectinib, and brigatinib are all approved for second-line therapy after progression on or intolerance to crizotinib. Clinical efficacy observed with these agents, particularly in the CNS prompted evaluating these agents as front-line therapy. Recently, in two separate phase III trials, alectinib has demonstrated superior clinical efficacy as front-l..... READ ARTICLE
Pulmonary Adenocarcinoma: Approaches to Treatment DOI:10.1016/B978-0-323-55433-6.00008-0
Authors: Shirish Gadgeel Editor: Leora Horn
